The role of aspirin in prevention of preeclampsia in twin pregnancies: does the dose matter?

Kalafat, Erkan
Shirazi, Amani
Thilaganathan, Basky
Khalil, Asma
Objective The use of aspirin in twin pregnancies for the prevention of preeclampsia is a controversial topic, and evidence on the required dose of aspirin is scarce. We aimed to assess the efficacy of 75 mg/day vs 150 mg/day aspirin for the prevention of preeclampsia in twin pregnancies. Study Design This is a retrospective cohort study of twin pregnancies managed at St George’s University Hospital between 2012 and 2019. The National Institute for Health and Care Excellence guideline published in 2010 has recommended low-dose aspirin to women at high risk of preeclampsia.1 Monochorionic and dichorionic twin pregnancies were included in the cohort. Pregnancies between 2010 and 2012 were excluded to ensure thorough implementation of the national guideline. High-order multifetal gestations and pregnancies complicated by fetal anomalies also were excluded. Twin pregnancies with any of these risk factors (hypertension in a previous pregnancy, chronic hypertension, renal disease, autoimmune disorder, diabetes, nulliparity, maternal age >40 years, pregnancy interval >10 years, body mass index >35 kg/m2, or family history of preeclampsia) as per the National Institute for Health and Care Excellence guideline were started on aspirin.1 The aspirin dose was changed from 75 mg/day to 150 mg/day after 2017, following reports of effective prevention of preeclampsia using aspirin 150 mg/day.2, 3, 4 The main outcome was preeclampsia diagnosed according to International Society for the Study of Hypertension in Pregnancy guideline.5 Hypertensive disorders of pregnancy (HDP) included preeclampsia or gestational hypertension. Results There were 630 pregnancies in the cohort; 404 received aspirin (108 received 150 mg/day and 296 received 75 mg/day), whereas 226 did not. There were 28 (4.4%) cases of preeclampsia and 47 (7.5%) cases of HDP in the cohort. No significant differences in maternal age (P=.510), nulliparity (P=.945), and chorionicity (P=.700) were observed between the 75 mg/day and 150 mg/day aspirin groups. The incidence of preeclampsia was similar between the aspirin 150 mg/day and no aspirin groups (1.8% vs 3.1%, P=.510). However, there was a trend toward a significant decrease in preeclampsia in those receiving aspirin 150 mg/day compared with 75 mg/day (1.8% vs 6.4%, P=.067). There were no statistically significant differences between aspirin 150 mg/day and the no aspirin groups regarding the incidence of HDP (1.8% vs 5.3%, P=.140), but the incidence of HDP was significantly lower in aspirin 150 mg/day group compared with the 75 mg/day group (1.8% vs 11.1%, P=.003) (Figure 1). The incidence of HDP was significantly greater in the aspirin 75 mg/day group compared with no aspirin (11.1% vs 5.3%, P=.018). We investigated the association of aspirin dose with HDP in a multivariable logistic regression model after adjusting for maternal age in years, chorionicity, and smoking during pregnancy. The reference group was the low-risk twin pregnancies who did not receive aspirin. The direction of the association changed from a significant increase in HDP (odds ratio, 2.01; 95% confidence interval, 1.03–4.18; P=.048) to a nonsignificant decrease (odds ratio, 0.31; 95% confidence interval, 0.05–1.16; P=.127) when the aspirin dose was increased from 75 mg/day to 150 mg/day. The incidence of preeclampsia (right) and hypertensive disorders of pregnancy (preeclampsia or gestational hypertension) (left) in women with twin pregnancies who received 150 mg/day vs 75 mg/day and no aspirin. The P values were calculated with the χ2 test. HDP, hypertensive disorders of pregnancy; PE, preeclampsia. Kalafat. The role of aspirin in prevention of preeclampsia in twin pregnancies: does the dose matter? Am J Obstet Gynecol 2020. Conclusion The incidence of hypertensive disorders in twin pregnancies with additional risk factors for preeclampsia was significantly lower in those receiving aspirin 150 mg/day compared with 75 mg/day.


The outcome of the multifetal pregnancy reduction procedures in a single centre: A report of 202 completed cases
Yilanhoglu, Necip Cihangir; Semiz, Altug; Arisoy, Resul; Kahraman, Semra; Gurkan, Ali Arslan (Elsevier BV, 2018-11-01)
Objective: To review the results of fetal reduction procedures in our institution, evaluate its effects on the pregnancy outcome in terms of miscarriage, preterm delivery, taking home healthy babies and discuss the factors that may have contributed to the outcome.
Is umbilicocerebral ratio better than cerebroplacental ratio for predicting adverse pregnancy and neonatal outcomes?
Kalafat, Erkan; Kalaylioglu, Zeynep; Thilaganathan, Basky; Khalil, Asma (Elsevier BV, 2020-09-01)
Objective A secondary analysis of the trial of randomized umbilical and fetal flow in Europe suggested that the umbilicocerebral ratio (UCR) provides better differentiation of neurodevelopmental outcome in the abnormal range compared with that of the cerebroplacental ratio (CPR).1 However, the reported superiority of UCR is controversial.2 This study aimed to compare the CPR and the UCR for predicting operative delivery for presumed fetal compromise and prolonged neonatal unit (NNU) admission in term fetus...
Incidence of postpartum hypertension within 2 years of a pregnancy complicated by pre-eclampsia: a systematic review and meta-analysis
Giorgione, V; Ridder, A.; Kalafat, E.; Khalil, A.; Thilaganathan, B. (Wiley, 2020-10-01)
Background Women with a history of hypertensive disorders of pregnancy (HDP) are at increased long-term risk of cardiovascular disease. However, there has been increasing evidence on the same risks in the months following birth. Objectives This review aims to estimate the incidence of hypertension in the first 2 years after HDP. Search strategy MEDLINE, Embase and Cochrane databases were systematically searched in October 2019. Selection criteria Observational studies comparing hypertension rate following H...
Efficacy of citalopram on climacteric symptoms
Kalay, Aysegul E.; Demir, Berfu; Haberal, Ali; Kalay, Mustafa; Kandemir, Omer (Ovid Technologies (Wolters Kluwer Health), 2007-03-01)
Objective: The aim of this study was to evaluate the efficacy of citalopram for climacteric symptoms and to assess the combined effect of citalopram and hormone therapy (HT) on climacteric symptoms in women inadequately responsive to HT alone.
Risk of operative delivery for intrapartum fetal compromise in small-for-gestational-age fetuses at term: an internally validated prediction model
Kalafat, Erkan; Morales-Rosello, Jose; Thilaganathan, Basky; Tahera, Fathema; Khalil, Asma (Elsevier BV, 2018-01-01)
BACKGROUND: Small-for-gestational-age fetuses are at an increased risk of intrapartum fetal compromise requiring operative delivery. Factors associated with the risk of intrapartum fetal compromise are yet to be established, and a comprehensive model accounting for both the antenatal and intrapartum variables is lacking.
Citation Formats
E. Kalafat, A. Shirazi, B. Thilaganathan, and A. Khalil, “The role of aspirin in prevention of preeclampsia in twin pregnancies: does the dose matter?,” AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, pp. 457–458, 2020, Accessed: 00, 2020. [Online]. Available: